Svb Leerink Weighs in on Radius Health Inc’s FY2023 Earnings (RDUS)

Radius Health Inc (NASDAQ:RDUS) – Analysts at Svb Leerink issued their FY2023 EPS estimates for Radius Health in a note issued to investors on Wednesday, May 8th. Svb Leerink analyst G. Porges anticipates that the biopharmaceutical company will earn $1.10 per share for the year.

A number of other equities analysts also recently issued reports on the company. HC Wainwright started coverage on Radius Health in a research note on Thursday, February 14th. They set a “neutral” rating and a $22.00 price target for the company. BidaskClub downgraded Radius Health from a “hold” rating to a “sell” rating in a research note on Wednesday, January 16th. Zacks Investment Research downgraded Radius Health from a “hold” rating to a “sell” rating in a research note on Thursday, January 17th. Cowen reiterated a “hold” rating on shares of Radius Health in a research note on Wednesday, May 8th. Finally, ValuEngine raised shares of Radius Health from a “sell” rating to a “hold” rating in a research report on Monday, April 1st. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $38.00.



RDUS stock opened at $20.19 on Monday. The stock has a market cap of $930.90 million, a price-to-earnings ratio of -4.14 and a beta of 0.98. The company has a debt-to-equity ratio of 2.97, a current ratio of 5.92 and a quick ratio of 5.79. Radius Health has a 52-week low of $12.81 and a 52-week high of $33.57.

Radius Health (NASDAQ:RDUS) last released its quarterly earnings results on Thursday, February 28th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.32. The business had revenue of $34.42 million during the quarter, compared to the consensus estimate of $33.99 million. Radius Health had a negative return on equity of 191.58% and a negative net margin of 176.84%.

In other news, Director Jessica Hopfield bought 12,800 shares of the company’s stock in a transaction on Tuesday, March 5th. The shares were purchased at an average price of $19.23 per share, with a total value of $246,144.00. Following the transaction, the director now directly owns 12,800 shares in the company, valued at $246,144. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Willard H. Dere sold 1,680 shares of Radius Health stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $22.22, for a total transaction of $37,329.60. Following the transaction, the director now directly owns 8,620 shares in the company, valued at approximately $191,536.40. The disclosure for this sale can be found here. 4.00% of the stock is owned by company insiders.

Several institutional investors have recently bought and sold shares of the business. BB Biotech AG lifted its position in shares of Radius Health by 1.8% during the 4th quarter. BB Biotech AG now owns 6,710,276 shares of the biopharmaceutical company’s stock worth $110,652,000 after buying an additional 120,000 shares in the last quarter. Vanguard Group Inc raised its holdings in shares of Radius Health by 1.5% in the 3rd quarter. Vanguard Group Inc now owns 3,571,571 shares of the biopharmaceutical company’s stock worth $63,574,000 after purchasing an additional 53,281 shares during the period. Vanguard Group Inc. raised its holdings in shares of Radius Health by 1.5% in the 3rd quarter. Vanguard Group Inc. now owns 3,571,571 shares of the biopharmaceutical company’s stock worth $63,574,000 after purchasing an additional 53,281 shares during the period. Artisan Partners Limited Partnership raised its holdings in shares of Radius Health by 1.1% in the 1st quarter. Artisan Partners Limited Partnership now owns 705,574 shares of the biopharmaceutical company’s stock worth $14,069,000 after purchasing an additional 7,872 shares during the period. Finally, Spark Investment Management LLC raised its holdings in shares of Radius Health by 15.5% in the 1st quarter. Spark Investment Management LLC now owns 677,800 shares of the biopharmaceutical company’s stock worth $13,515,000 after purchasing an additional 91,200 shares during the period.

About Radius Health

Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.

Featured Article: Benefits of owning preferred stock

Earnings History and Estimates for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.